Tolan Park Medical Building
Detroit, Michigan, 48201, United States
NCT Number: NCT04231708
This preliminary study is designed to evaluate mechanisms by which excitatory dorsolateral prefrontal cortex (dlPFC) repetitive transcranial magnetic stimulation (rTMS) (vs. sham) and pharmacological stress (vs. placebo) alter behavior in non-treatment seeking individuals with opioid use disorder (OUD). Specific Aims are to (1) Evaluate how stress impacts domains of behavior including (1a) executive function and (1b) opioid-seeking behavior; and (2) Determine whether rTMS stimulation attenuates (2a) executive dysfunction, (2b) stress-reactivity, and (2c) opioid-seeking in individuals with OUD not receiving treatment.
Trial opening soon.
Get Notified21 year–60 year
All sexes
Interventional
Phase 2
Detroit, Michigan, 48201, United States
This study will use a double-blind, 10Hz left dlPFC rTMS (vs. sham) and pharmacological stressor ([yohimbine + hydrocortisone] vs. placebo) within-subject, randomized crossover design. Each participant will complete 4 sessions (stressor vs. placebo, crossed with rTMS vs. sham), each separated by at least 1 week. Participants will complete these 4 (2x2 within subject) test conditions in randomized order: sham rTMS/placebo stress, sham rTMS/active stress, active rTMS/ placebo stress, and active rTMS/active stress.
The PI will perform randomization using a Latin Square and will assign participants to conditions and prepare medication (stressor or placebo) for each participant's sessions. The PI will keep others blinded and will not be involved in study assessments.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
10Hz rTMS over the left dlPFC
lactose (inside capsule)
inactive stimulation over the left dlPFC
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
measures cognitive control in response to opioid-related words.
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
measures verbal working memory. Participants are asked to repeat strings of numbers of increasing length, both forward and backward.
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
measures ability to shift set and assesses cognitive flexibility.
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
subjects rate the unpleasantness and arousal of different emotional pictures
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
subjects rate their positive and negative affect
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
subjects rate their level state anxiety
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
Participants respond to a visual target that follows 2 different cues: incentive or non-incentive. No reward or punishment occurs on non-incentive trials. On incentive trials, participants must respond within a fixed amount of time. In the reward condition, responses within that time result in receiving the incentive , else nothing. In the punishment condition, the participant will lose money if they do not respond within the time limit
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
Participants perform a brief (<1min) hypothetical version of the traditional monetary task with a 5-trial adjusting delay previously validated to rapidly assess discount rate
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
participants choose hypothetically between a constant amount of their preferred opioid ($10 unit dose) or money ($2)
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
millimeters mercury (mmHg)
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
millimeters mercury (mmHg)
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
beats per minute
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
measure of the activity of the HPA axis
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
indirect measure of adrenergic stimulation
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
indirect measure of dopamine stimulation
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
indirect measure of brain derived neurotrophic factor activation
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
Prefrontal gamma (25-100 Hz) EEG power, relative to slow-wave EEG power, is a stress biomarker
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
Desire for Drug Questionnaire total score; higher scores indicate greater craving
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
Opiate-32 questionnaire agonist symptom total score; higher scores indicate greater opioid symptom severity
Time frame: change from pre- to post-intervention in each of 4 sessions (through study completion, about 1 month total)
Opiate-32 questionnaire withdrawal symptom total score; higher scores indicate greater withdrawal severity
Wayne State University
Other
Effects of Pharmacological Stress and Repetitive Transcranial Magnetic Stimulation Interventions on Executive Function in Opioid Use Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07176351
Chemically-Induced Disorders, Mental Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT07362082
Chemically-Induced Disorders, Mental Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT07725289
Adolescent Substance Use, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT07348796
Chemically-Induced Disorders, Mental Disorders
San Antonio, Texas, United States
View Trial Details